1  in myocytes lacking the regulatory protein, 
phospholemman.                                          
 
     2 tion alters the interaction of Na/K-pump and 
phospholemman.                                          
 
     3               We observed down-regulation of 
phospholemman (
a phosphoprotein associated with anion ch
 
     4     We previously identified FXYD1 (encoding 
phospholemman; 
a protein containing the motif phenylalan
 
     5                             We conclude that 
phospholemman and Na/K-pump are in very close proximity 
 
     6 r inward-rectifier Cl- channels, e.g. ClC-2, 
phospholemman and the channel in Xenopus oocytes.       
 
     7 y of small membrane proteins, represented by 
phospholemman and the gamma subunit of Na,K-ATPase, was 
 
     8 t (CFP/YFP) fusion proteins of Na/K pump and 
phospholemman and whether phospholemman phosphorylation 
 
     9                                              Phospholemman antibodies precipitated all three Na,K-ATP
 
    10 pitation and functional studies suggest that 
phospholemman associates with the Na/K-pump (NKA) and me
 
    11 PKA targets, such as phospholamban at Ser16, 
phospholemman at Ser68 and cardiac myosin-binding protei
 
    12  of the Na(+),K(+)-ATPase modulating protein 
phospholemman at serine residue 63 (S63 PLM).           
 
    13 Much like phospholamban regulation of SERCA, 
phospholemman exists as both a sodium pump inhibiting mo
 
    14  not NKA-alpha1 was coupled to a decrease in 
phospholemman expression and phosphorylation, which woul
 
    15                                 Furthermore, 
phospholemman (
FXYD1) inhibits pump function without sig
 
    16                                              Phospholemman (
FXYD1) is a homolog of the Na,K-ATPase ga
 
    17                                              Phospholemman (
FXYD1) is a single-transmembrane protein 
 
    18  isoform and consistent with the presence of 
phospholemman in both neurons and glia.                 
 
    19                            Here we show that 
phospholemman is highly expressed in selected structures
 
    20 t nearly abolished when co-expressing excess 
phospholemman lacking YFP.                              
 
    21 e-spanning membrane proteins such as cardiac 
phospholemman, 
Mat-8 and renal CHIF, large ion conductan
 
    22 sphorylation signature associates with other 
phospholemman molecules but not with the pump.          
 
    23 ospholemman phosphorylation, consistent with 
phospholemman multimerization.                          
 
    24                                              Phospholemman oligomers exist in cardiac muscle.        
 
    25 olubilized crude membranes using either anti-
phospholemman or anti-Na,K-ATPase antibodies.           
 
    26 without any differences in membrane markers (
phospholemman, 
phosphalamban, dihydropyridine-binding co
 
    27 s of Na/K pump and phospholemman and whether 
phospholemman phosphorylation alters such FRET.         
 
    28  very close proximity (FRET occurs) and that 
phospholemman phosphorylation alters the interaction of 
 
    29                             This agreed with 
phospholemman phosphorylation measurements: by protein k
 
    30  photobleach), and this FRET was enhanced by 
phospholemman phosphorylation, consistent with phosphole
 
    31 nt experimental approaches demonstrated that 
phospholemman physically associated with the Na,K-ATPase
 
    32                                    In heart, 
phospholemman (
PLM) inhibits NKA activity by reducing it
 
    33                                              Phospholemman (
PLM) is a member of the FXYD ('fix-it') f
 
    34                                              Phospholemman (
PLM) is a small (72-amino acid) transmemb
 
    35                                              Phospholemman (
PLM) is a small transmembrane cardiac pro
 
    36 e NKA-associated small transmembrane protein 
phospholemman (
PLM) mediates beta-adrenergic-induced NKA
 
    37                                              Phospholemman (
PLM) or FXYD1 is a major cardiac myocyte 
 
    38                                              Phospholemman (
PLM) phosphorylation mediates enhanced Na
 
    39                   The cardiac phosphoprotein 
phospholemman (
PLM) regulates the cardiac sodium pump, a
 
    40                                      Because 
phospholemman (
PLM) regulates the Na(+)/K(+) pump (NKA) 
 
    41                      The sarcolemmal protein 
phospholemman (
PLM) was found associated with the Na/K A
 
    42 afficking of two FXYD family members, FXYD1 (
phospholemman (
PLM)) and FXYD7.                         
 
    43         We have demonstrated previously that 
phospholemman (
PLM), a 15-kDa integral sarcolemmal phosp
 
    44                           Here, we show that 
phospholemman (
PLM), a 15-kDa integral sarcolemmal phosp
 
    45  Previous reports have demonstrated that the 
phospholemman (
PLM), a 72-residue plasma-membrane protei
 
    46                                              Phospholemman (
PLM), a major membrane substrate for phos
 
    47                           We have found that 
phospholemman (
PLM), a member of the FXYD family and reg
 
    48                                              Phospholemman (
PLM), a member of the FXYD family of prot
 
    49                                              Phospholemman (
PLM), a member of the FXYD family of smal
 
    50 arts) expression of Na/K-ATPase isoforms and 
phospholemman (
PLM), a putative Na/K-ATPase regulatory s
 
    51 eased, the palmitoylated regulatory protein, 
phospholemman (
PLM), and the cardiac Na/Ca exchanger (NC
 
    52                                              Phospholemman (
PLM), the principal quantitative sarcolem
 
    53                                              Phospholemman (
PLM), the principal sarcolemmal substrate
 
    54 eraction with a small transmembrane protein, 
phospholemman (
PLM).                                    
 
    55                      Phospholamban (PLB) and 
phospholemman (
PLM, also called FXYD1) are small transme
 
    56                     Serine 68-phosphorylated 
phospholemman (
pSer-68-PLM) inhibits NCX1 activity.     
 
    57  Antibodies against the C-terminal domain of 
phospholemman reduced Na,K-ATPase activity in vitro with
 
    58                                              Phospholemman regulates the plasmalemmal sodium pump in 
 
    59                                              Phospholemman was particularly enriched in choroid plexu
 
    60        In cardiac muscle, a subpopulation of 
phospholemman with a unique phosphorylation signature as